Characteristics of 50 children and adolescent at diagnosis of type 1 diagnosis (mean±SD)
| All subjects mean±SD n=50 | Slow progressor mean±SD n=30 | Rapid progressor mean±SD n=20 | P value | |
| Male/female | 22/28 | 15/15 | 7/13 | 0.295 |
| Year of diagnosis | 2009±3 | 2008±3 | 2010±3 | 0.108 |
| Age at diagnosis (years) | 10.6±2.5 | 11.1±2.6 | 10.0±2.3 | 0.132 |
| HbA1c (mmol/mol) | 99±26 | 96±29 | 104±19 | 0.250 |
| HbA1c (%) | 11.2±4.5 | 10.9±4.8 | 11.7±3.9 | 0.250 |
| Blood glucose (mmol/L) | 28.8±14.9 | 25.4±9.4 | 33.6±19.7 | 0.068 |
| BMISDS | −0.07±1.26 | 0.08±1.40 | −0.29±1.02 | 0.339 |
| pH | 7.35±0.09 | 7.36±0.07 | 7.32±0.11 | 0.129 |
| Ketoacidosis (pH<7.0) | 7/48 | 2/28 | 5/20 | 0.084 |
| GADA detectable | 33/42 | 18/25 | 15/17 | 0.208 |
| IA-2A detectable | 32/42 | 17/25 | 15/17 | 0.131 |
| GADA and IA-2A | 29/42 | 14/25 | 15/17 | 0.027 |
| HLA-risk profile | 29/39 | 16/24 | 13/15 | 0.164 |
Differences in the slow versus rapid progressor group. P value <0.05 was considered as statistically significant.
BMISDS, body mass index SD scores; GADA, glutamic acid decarboxylase antibodies; IA-2A, islet antigen-2 antibodies.